Consensus Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2026 BST			5-day change	1st Jan Change
82.21 ^USD	-2.71%		-4.50%	+5.65%

05-15	Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses	RE
05-12	Kymera Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 09:20 AM

Evolution of the Average Target: Kymera Therapeutics, Inc.

Evolution of the Target Price: Kymera Therapeutics, Inc.

Changes in Analyst Recommendations: Kymera Therapeutics, Inc.

e94c8938a7ffbec0a02.MkuD0TuzK3ScmfT6mslljILSAMoozxEtz0fYXmzsF88.fgPGp2z2fzOt64OC15o_zbO0N4xwgCkbpAywGF2Kdph4E_qIVfx-Ef-hpQ~350a76095f6358a5424c843306b27dc3

Analysts' recommendations: Kymera Therapeutics, Inc.

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
03-03	UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating	MT
12-22	B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating	MT
12-16	Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says	MT
12-16	RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk	MT
12-11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
12-09	Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating	MT
12-09	Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating	MT
12-09	Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating	MT
11-25	Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating	MT
24/10/25	B. Riley Boosts Price Target on Kymera Therapeutics to $80 From $60, Keeps Buy Rating	MT
21/10/25	Mizuho Initiates Kymera Therapeutics at Outperform With $81 Price Target	MT
30/09/25	Truist Raises Price Target on Kymera Therapeutics to $68 From $53, Keeps Buy Rating	MT
17/09/25	Barclays Initiates Kymera Therapeutics at Overweight With $60 Price Target	MT
16/09/25	RBC Initiates Kymera Therapeutics at Outperform, Speculative Risk With $70 Price Target	MT
27/06/25	Oppenheimer Adjusts Kymera Therapeutics Price Target to $53 From $56, Maintains Outperform Rating	MT
26/06/25	HC Wainwright Adjusts Price Target on Kymera Therapeutics to $60 From $54, Maintains Buy Rating	MT
03/06/25	Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says	MT
03/06/25	Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating	MT
03/06/25	B. Riley Upgrades Kymera Therapeutics to Buy From Neutral, Adjusts Price Target to $60 From $38	MT
03/06/25	Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49	MT
02/06/25	BofA Securities Upgrades Kymera Therapeutics to Buy From Neutral, $51 Price Target; Shares Rise	MT
13/05/25	UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating	MT
12/05/25	B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating	MT
13/03/25	Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	KYMERA THERAPEUTICS, INC.					+43.87%
	LONZA GROUP AG					+42.59%
	BEONE MEDICINES AG					+40.27%
	REVOLUTION MEDICINES, INC.					+24.47%
	IQVIA HOLDINGS INC.					+35.17%
	CELLTRION, INC.					+39.21%
	IONIS PHARMACEUTICALS, INC.					+35.77%
	EUROFINS SCIENTIFIC SE					+19.34%
	Average					+35.09%
	Weighted average by Cap.					+35.83%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

82.21USD

Average target price

118.27USD

Spread / Average Target

+43.87%

High Price Target

140.00USD

Spread / Highest target

+70.30%

Low Price Target

91.00USD

Spread / Lowest Target

+10.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Canaccord Genuity
UBS
B. Riley
RBC Capital Markets
Mizuho Securities
Oppenheimer
Truist Securities
Morgan Stanley
Barclays
HC Wainwright
Stifel Nicolaus
BofA Securities
Citigroup
BMO Capital
Wells Fargo Securities
Piper Sandler
Wolfe Research
Credit Suisse
Raymond James
Goldman Sachs
SVB Securities LLC
Jefferies & Co.
Berenberg Bank
JPMorgan Chase
Brookline Capital Management